The Efficacy and Safety of Albumin‐Bound Paclitaxel Combined With Anlotinib and <scp>PD</scp>‐1/<scp>L1</scp> Inhibitors For Treating Patients With Extensive‐Stage Small Cell Lung Cancer and Brain Metastasis: A Retrospective Cohort Study
The combination of nab-ptx, anlotinib, and PD-1/L1 inhibitors exhibited substantial efficacy and acceptable safety in the treatment of BM from ES-SCLC. This novel therapeutic approach holds promise for improving the outcomes for patients with this challenging disease. Further studies are needed to validate these findings and investigate the long-term benefits of this combination regimen.
Authors
- Yi Peng (ORCID: https://orcid.org/0000-0002-5319-1336)
- Xiaobing Li (ORCID: https://orcid.org/0000-0002-3332-0575)
- Yuebing Wu
- Jing Tang (ORCID: https://orcid.org/0000-0003-1013-147X)
- De Pei Wu
Institutions
- Hubei Cancer Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/cam4.70449
- Citations
- 5
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.41
Funders
- Natural Science Foundation of Hubei Province